Indee Labs Awarded Contract from the National Cancer Institute

BERKELEY, Calif.–(BUSINESS WIRE)–Indee Labs is a biotechnology company developing the µVS Delivery System^TM for non-viral intracellular or gene delivery. The team at Indee Labs was recently awarded a contract from the National Cancer Institute to develop the µVS Delivery System^TM for T cell immunotherapy discovery, development and manufacturing.

“T cell immunotherapies have revolutionized how we treat disease; however, the processes to discovery, develop and manufacture these interventions are fraught with issues. We’re excited to be supported by the NCI to develop our novel, non-viral gene delivery system called the µVS Delivery System^TM to insert transgenes for CAR-T and TCR-T cell products at clinical scale at a…